Because of its very short half-life, native GLP-1 cannot be used for therapeutic purposes
The expression and distribution of FFARs such as GPR40, GPR119, and GPR120 in L and cells and glucose, along with their dual effects on insulin and GLP-1 secretion, have made them attractive therapeutic targets, leading to the development of agonists for these receptors for the treatment of T2DM [150,151,152,153,154]
In addition to treating type 2 diabetes, these medications can help people lose weight by lowering appetite, slowing digestion, and helping the body regulate blood sugar more effectively
It is specifically designed to help improve blood sugar levels in adults with type 2 diabetes
Contact your PlexusDx clinician if symptoms persistthey can adjust your dose speed or explore alternative therapies like oral semaglutide without interrupting your weight loss journey
Freeman JS: Optimizing outcomes for GLP-1 agonists